Introduction . The use of thrombopoietin receptor agonists, especially eltrombopag, in the treatment aplastic anemia (AA) patients who did not respond to previous immunosuppressive therapy (IST), is accompanied by development a hematological response 40–60 % patients. Aim — study effi cacy using eltrombopag programs for AA refractory IST. Methods included 20 were treated at National Research Ce...
